Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.
This page provides a historical news archive for Mural Oncology plc (formerly Nasdaq: MURA), a biotechnology company described in its public communications as a clinical-stage immuno-oncology company. The company focused on using a protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer and maintained its registered office in Dublin, Ireland, with primary facilities in Waltham, Massachusetts.
The news flow around Mural Oncology includes several key themes documented in its press releases. One major strand is the clinical development and subsequent discontinuation of its lead product candidate, nemvaleukin alfa. Announcements in March and April 2025 reported that the Phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer did not meet its primary endpoint and that, after reviewing additional data from the Phase 2 ARTISTRY-6 trial in melanoma, the company decided to discontinue all clinical development of nemvaleukin and terminate other research and development activities, including IL-18 and IL-12 programs.
Another central theme in Mural Oncology’s news record is its exploration of strategic alternatives and eventual acquisition. On April 15, 2025, the company announced that it would explore strategic alternatives focused on maximizing shareholder value, and later updates described cost-conservation measures, including a workforce reduction of approximately 90%. On August 20, 2025, Mural Oncology and XOMA Royalty Corporation announced a definitive transaction agreement under which XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, would acquire the entire issued and to be issued share capital of Mural via an Irish High Court sanctioned scheme of arrangement.
Subsequent news items document shareholder approvals at meetings held on October 24, 2025, the sanction of the scheme by the High Court of Ireland, and the effective date of the acquisition on December 5, 2025. The company also announced that admission of Mural shares to trading on the Nasdaq Global Market was cancelled with effect from the evening of December 4, 2025. Together, these releases provide a detailed timeline of Mural Oncology’s transition from an independent Nasdaq-listed biotech to a wholly owned subsidiary of XOMA Royalty Corporation.
Mural Oncology (Nasdaq: MURA) announced that the scheme of arrangement under Irish law to sell the company to XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty (Nasdaq: XOMA), became effective on 5 December 2025.
Cancellation of MURA trading on the Nasdaq Global Market took effect at 8:00 pm ET on 4 December 2025. Cash consideration payments to scheme shareholders will begin as soon as practicable and will be distributed by no later than 19 December 2025, with DTC participant accounts expected to be credited and cheques distributed accordingly.
Mural Oncology (Nasdaq: MURA) announced that the High Court of Ireland sanctioned a scheme of arrangement under which XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty (Nasdaq: XOMA), will acquire all issued and to be issued share capital of Mural.
The Scheme is expected to become effective on delivery of the Court Order to the Irish Registrar of Companies on 5 December 2025; 4 December 2025 is expected to be the last trading day for MURA on Nasdaq, with cancellation of admission effective 4 December 2025 at 8:00 pm ET. Distribution of cash consideration to Scheme shareholders is expected to begin as soon as practicable after the Effective Date and will be completed by no later than 19 December 2025.
Mural Oncology (Nasdaq: MURA) announced the final cash consideration for its agreed acquisition by XOMA Royalty (Nasdaq: XOMA). The Additional Price Per Share was finally determined as $0.000, making the total cash consideration payable to Mural shareholders on closing $2.035 per share.
The Acquisition will be effected via an Irish High Court‑sanctioned scheme of arrangement and is expected to close in early December 2025, subject to satisfaction of outstanding closing conditions and court sanction.
Mural Oncology (Nasdaq: MURA) shareholders approved the proposed acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, at meetings held October 24, 2025 in Dublin.
The transaction values Mural's issued and to be issued share capital at approximately $36.2 million. Under the agreement each Mural share will receive a Base Price Per Share of $2.035 payable at closing, plus an Additional Price Per Share up to $0.205 depending on Closing Net Cash. The deal is expected to close in Q4 2025, subject to customary conditions and sanction of the High Court of Ireland.
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, has initiated the mailing of its definitive proxy statement regarding the proposed acquisition by XOMA Royalty (Nasdaq: XOMA). The acquisition will be executed through XRA 5 Corp, a wholly-owned subsidiary of XOMA Royalty, via an Irish High Court sanctioned scheme of arrangement.
The company has scheduled two crucial meetings for October 24, 2025 in Dublin, Ireland: a Scheme Meeting at 10:30 AM Irish time, followed by an Extraordinary General Meeting (EGM) at 10:45 AM. The proxy statement contains detailed information about the acquisition terms, voting instructions, and treatment of Mural equity awards.
Mural Oncology (NASDAQ:MURA) has entered into a definitive agreement to be acquired by XRA 5 Corp., a subsidiary of XOMA Royalty (NASDAQ:XOMA). The acquisition terms include a base price of $2.035 per share with a potential additional payment of up to $0.205 per share based on Mural's closing net cash position.
The base offer values Mural at approximately $36.2 million and represents a 13.1% premium to Mural's closing price on August 19, 2025, and a 97.6% premium to its undisturbed price on April 14, 2025. The transaction, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.
Mural Oncology (NASDAQ: MURA) reported its Q2 2025 financial results amid significant organizational changes. The company, which discontinued all clinical development of its lead product nemvaleukin alfa in April 2025, implemented a 90% workforce reduction and terminated all research programs, including IL-18 and IL-12 initiatives.
Financial highlights include cash and equivalents of $77.1 million as of June 30, 2025, with projected year-end balance of $43-48 million. Q2 2025 saw R&D expenses decrease to $23.3 million from $27.5 million year-over-year, while G&A expenses increased to $8.1 million from $6.7 million. The company reported a net loss of $48.0 million, up from $31.6 million in Q2 2024, primarily due to $17.5 million in restructuring and impairment charges.
[ "Maintained significant cash position of $77.1 million as of June 30, 2025", "Reduced R&D expenses by 15.3% year-over-year", "Implemented aggressive cost-cutting measures to preserve cash" ]Mural Oncology (NASDAQ: MURA), a clinical-stage immuno-oncology company, has disclosed its securities information in compliance with Irish Takeover Rules. As of May 1, 2025, the company reported 17,268,881 ordinary shares outstanding with a par value of $0.01 each. Additionally, as of March 31, 2025, Mural has 1,121,460 non-vested restricted stock units and 3,725,736 stock options outstanding. Each restricted stock unit converts to one ordinary share upon vesting, while each stock option allows the purchase of one ordinary share at the specified exercise price. The ordinary shares trade under the International Securities Identification Number IE000LK2BOB4.
Mural Oncology has filed an Opening Position Disclosure under Rule 8.1(a) and (b) of the Irish Takeover Panel Act as an offeree company. The disclosure, dated April 29, 2025, reveals the following key details:
CEO Caroline Loew holds 43,622 ordinary shares (0.25% of total issued share capital) and 865,908 underlying stock options. The board includes Scott Jackson, Francis Cuss, George Stanley Golumbeski, Benjamin Hickey, and Sachiyo Minegishi, each holding various stock options totaling 967,026 combined.
The disclosure confirms no interests or short positions in relevant securities, cash-settled derivatives, or stock-settled derivatives. Additionally, there are no indemnity arrangements or agreements relating to voting rights or future acquisitions.
Mural Oncology (Nasdaq: MURA) has announced the discontinuation of all clinical development of nemvaleukin alfa following unsuccessful trial results. The decision comes after reviewing data from the phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer.
The company reported $144.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024. In response to these developments, Mural plans to:
- Reduce its workforce by approximately 90%
- Explore strategic alternatives to maximize shareholder value
- Engage Lucid Capital Markets, as financial advisor
The ARTISTRY-6 trial's cohort 2, involving 92 patients with mucosal melanoma, failed to achieve its primary endpoint. Additionally, cohort 3, testing less-frequent intravenous dosing in cutaneous melanoma patients, showed insufficient activity to warrant continuation.
FAQ
What is the current stock price of Mural Oncology PLC (MURA)?
What is the market cap of Mural Oncology PLC (MURA)?
